Objective: To study the clinical efficacy of Quetiapine to treat the hospitalized patients with acute delirium.Methods: There were 87 cases diagnosed as delirium.They were randomly divided into two groups, the study group had 44 cases and the control group had 43 cases.In the original disease were treated actively simultaneously, we amalgamative used Quetiapine in the study group and Olanzapine in the control group.Before the treatment, one week and two weeks after the treatment, we respectively used BPRS, CAM-CR, CGI, and TESS in turn to give grades.Results: ①After the treatment, the effective rate was 84.66％ in Quetiapine group and 85.37％ in Olanzapine group, there was no significant difference between the two groups (P＞0.05).②To compare with before the treatment, the grades of CAM-CR and CGI had improved in both groups after one week treatment (P＜0.05), and there were more improvement after two weeks treatment (P＜ 0.01), there was no significant difference between the two groups (P＞0.05).③The overall incidence of adverse events of Olanzapine group was significantly higher than those of the Quetiapine group, the difference was significant (P＜0.05).Conclusion: Compared with Olanzapine, Quetiapine has the same effect in treating delirium, and has fewer adverse reactions, so Quetiapine can be the first-line drug for the treatment of delirium.%目的:研究喹硫平对综合医院住院患者伴急性谵妄的临床疗效.方法:将87例确诊为急性谵妄的患者随机分为两组,研究组44例和对照组43例.在积极治疗原发病的同时,治疗组患者合并使用喹硫平治疗,对照组患者合并使用奥氮平治疗.在治疗前,治疗1周、2周后分别使用简明精神病量表(BPRS)、谵妄评定量表(CAM-CR)、临床总体印象量表(CGI)和药物副作用量表(TESS)给予评分.结果:①喹硫平组和奥氮平组治疗后显效率分别为84.66%与85.37%,两组显效率差异无统计学意义(P>0.05).②与治疗前相比,研究组和对照组在治疗1周后的CAM-CR和CGI量表评分均有改善(P<0.05);治疗2周后,研究组和对照组患者改善更明显(P<0.01),两组间差异无统计学意义(P>0.05).③不良反应总的发生率奥氮平组明显高于喹硫平组,两组差异有统计学意义(P<0.05).结论:喹硫平与奥氮平治疗谵妄疗效相当,喹硫平不良反应小,可以作为一线药物用于谵妄的治疗.
展开▼
